Initial Gamma Knife Radiosurgery for Large or Documented Growth Asymptomatic Meningiomas: Long-Term Results From a 27-Year Experience

Junyi Fu†, Lisha Wu‡, Chao Peng§, Xin Yang¶, Hongji You*, Linhui Cao, Yinhui Deng and Jinxiu Yu*

Objective: The aims of this study were to investigate the long-term outcomes of initial Gamma Knife radiosurgery (GKRS) for large (≥20 mm) or documented growth asymptomatic meningiomas.

Design and Methods: This was a single-center retrospective study. Fifty-nine patients with large (≥20 mm) or documented growth asymptomatic meningiomas undergoing initial GKRS were enrolled. The median age was 56 (range, 27–83) years. The median time of follow-up was 66.8 (range, 24.6–245.6) months, and the median tumor margin dose was 13.0 Gy (range, 11.6–22.0 Gy).

Results: Tumors shrunk in 35 patients (59.3%) and remained stable in 23 (39.0%). One patient (1.7%) experienced radiological progression at 54 months after GKRS. The PFS was 100%, 97%, and 97% at 3, 5, and 10 years, respectively. Nine patients (15.3%) occurred new neurological symptoms or signs at a median time of 8.1 (range, 3.0–81.6) months. The symptom PFS was 90% and 78% at 5 and 10 years, respectively. Fifteen patients (25.4%) occurred peritumoral edema (PTE) at a median time of 7.2 (range, 2.0–81.6) months. One patient underwent surgical resection for severe PTE. In univariate and multivariate analysis, Only tumor size (≥25 mm) and maximum dose (≥34 Gy) were significantly associated with PTE [hazard ratio (HR)=3.461, 95% confidence interval (CI)=1.157–10.356, p=0.026 and HR=3.067, 95% CI=1.068–8.809, P=0.037, respectively].

Conclusions: In this study, initial GKRS can provide a high tumor control rate as well as an acceptable rate of complications in large or documented growth asymptomatic meningiomas.
meningiomas. GKRS may be an alternative initial treatment for asymptomatic meningiomas.

**Keywords:** peritumoral edema, gamma knife, stereotactic radiosurgery, asymptomatic meningioma, progression-free survival

**INTRODUCTION**

Meningiomas are the most common intracranial benign tumors, which represent almost 13%–37.6% of all intracranial tumors (1–4). Of those meningiomas with documented WHO grade, 80.5% are grade I, 17.7% are grade II and 1.7% are grade III (4). As a result of advancement and increased application in magnetic resonance imaging (MRI) and computed tomography (CT), detection of asymptomatic meningiomas is becoming increasingly prevalent. Initial managements for asymptomatic meningiomas include observation, surgical resection and radiotherapy. However, the best treatment still remains controversial.

In most instances, many asymptomatic meningiomas has an indolent natural course. Only a small proportion of patients become symptomatic. In previous studies, 24%–92% of those meningiomas will increase in size under observation after a period of more than 4 years (1, 2, 5–10). Observation is a reasonable treatment option for those slow-growing and small asymptomatic tumors. But it may increase the treatment risk due to enlarged tumors and patient age. In a population-based analysis, the use of primary observation increased for smaller tumors (<2 cm), relative to surgery and radiation (11). In a recent meta-analysis, those tumors with larger size were likely to be symptomatic (12). Therefore, treatment should be recommended for large tumors, symptomatic tumors and those documented growth. Surgical resection is a better choice for tumor removal. But it is an invasive treatment, depends on tumor location and can cause significant morbidity (13). Gamma knife radiosurgery (GKRS) is more appealing than surgical resection, which is a less invasive treatment with a low morbidity.

There had been several publications reported the efficacy and safety of GKRS as primary or adjuvant treatment for asymptomatic meningiomas. These results showed a low tumor progression rate of 0–5.9%, and an acceptable rate of complications ranged from 2.4% to 20.5% after GKRS (7, 10, 14, 15). However, many patients in these studies had prior surgery or radiotherapy, peritumoral edema (PTE) or small tumors (<20 mm). The long-term outcomes of initial GKRS for asymptomatic meningiomas still need to be demonstrated. Therefore, we performed a single-center retrospective study consisting of patients with previous untreated, non-PTE and mainly large (≥20 mm) asymptomatic meningiomas.

**METHODS**

**Patients Population**

The medical records of meningioma patients from the single-center that underwent GKRS between December 1993 and December 2017 were retrospectively reviewed. There were 340 patients had complete clinical data and sufficient follow-up (≥24 months) in our hospital. Finally, 59 patients were included in this study. The GKRS inclusion criteria were shown in Figure 1. This study was approved by the institutional committee of the Second Affiliated Hospital of Guangzhou Medical University.

Inclusion criteria of this study: 1) MRI and/or CT findings suggested the diagnosis of meningioma, as interpreted by experienced clinicians and radiologists; 2) tumors with homogeneously contrast enhancement, dural tail and no perilesional edema; 3) the initial treatment was GKRS, no prior surgery or radiotherapy for the meningiomas; 4) no neurological symptoms or signs caused by the tumor; 5) large tumors (≥20 mm), or those small tumors with documented growth were included; 6) all of patients had complete medical records, at least one radiological and clinical evaluations with minimum follow-up of 24 months. Patients with neurofibromatosis type 2-associated meningiomas and PTE were excluded.

**Radiological and Clinical Evaluations**

All of asymptomatic meningioma patients were required to take routine clinical and radiological follow-up evaluations at 6 months initially and thereafter yearly. The follow-up evaluations were evaluated by experienced clinicians and radiologists. Tumor volume was based on ABC/2 formula: (A) maximum tumor diameter on axial plane; (B) diameter perpendicular to (A), and (C) maximum height on sagittal/coronal plane (16). Tumor shrinkage was defined as a reduction in tumor size at least 20% in any diameter. Stable tumor was defined as a change in tumor size within 20% in any diameter. Tumor progression was defined as an increase in tumor size at least 20% in any diameter. New neurological symptoms or signs after GKRS were recorded. Radiation related adverse effects and requiring treatment were reported.

**Gamma Knife Radiosurgery Technique**

Before April 2014, all of the patients were treated with Leksell Gamma Knife Unit B. Leksell Gamma Knife Perfection Unit (Elekta Instrument, Inc.) was used from April 2014 to the present. Patients were placed with Leksell stereotactic frame G and underwent stereotactic MR imaging with contrast through the entire brain for target delineation. GKRS plan was designed by a radiation oncologist, medical physicist, and neurosurgeon. 4 or 8 mm collimator was used for better conformality.

**Statistical Analysis**

IBM’s SPSS (version 21.0) was used for statistical analyses. Univariate and multivariate analysis of risk factors associated with PTE after GKRSs and symptom progression were carried out with Log-rank test statistics and a step forward likelihood ratio method of Cox proportional hazard models respectively. Kaplan-
Meier curves were plotted for progression-free survival (PFS), PTE and symptom progression. Probability values <0.05 were defined as statistically significant.

**RESULTS**

**Patient Characteristics**

Characteristics of patients were showed in Table 1. Fifty-nine patients who met inclusion criteria were included in this study. Of the 59 patients, 15 (25.4%) were male and 44 (74.6%) were female. The median age was 56 (range, 27–83) years. The median time of follow-up was 66.8 (range, 24.6–245.6) months. The median size was 22.0 (range, 15.7–57.0) mm. The median tumor volume was 3.9 (range, 2.5–6.8) ml. Two patients with tumor size <20 mm were documented with tumor growth on radiologic surveillance and enrolled in this study. The number of tumor size ≥30 mm was 12 (20.3%). The falx/parasagittal region was the most frequent tumor location, followed by the middle fossa (sphenoid/parasellar).

All of patients underwent single fraction GKRS as initial treatment for meningiomas. The median margin dose was 13.0 (range, 11.6–20.0) Gy at a median prescription isodose 40% (range, 35%–55%). The median maximum dose was 32.0 (range, 25.1–50.0) Gy (Table 1).

**Radiological and Symptom PFS**

Overall, 58 patients (98.3%) were confirmed as tumor control after a median follow-up time of 66.8 (range, 24.6–245.6) months. Tumors shrunk in 35 patients (59.3%) and remained stable in 23 patients (39.0%). One patient (1.7%) experienced radiological progression at 54 months after GKRS. The PFS was 100%, 97%, and 97% at 3, 5, and 10 years, respectively (Figure 2) (Table 2).

The symptom PFS was defined as the time interval between the time of occurrence of new neurological symptoms or signs and the time of GKRS in this study. Nine patients (15.3%) occurred new neurological symptoms or signs after GKRS at a median time of 8.1 (range, 3.0–81.6) months. Of the nine patients, seven patients presented with new neurological symptoms or signs might be due to PTE. Another two patients

![Figure 1](image-url)
presented with memory loss and cranial nerve deficit did not occur PTE after GKRS. The symptom PFS was 90% and 78% at 5 and 10 years, respectively (Figure 3) (Table 2).

**Complications After GKRS**

Seventeen patients (28.8%) developed complications after GKRS, including 15 patients (25.4%) with PTE and 2 patients with symptom unrelated with PTE. The median time of PTE was 7.2 (range, 2.0–81.6) months. Of these PTE patients, eight patients (13.6%) were asymptomatic PTE. Another seven patients (11.8%) presented with symptomatic PTE. Among of them, one patient underwent surgical resection for severe PTE after GKRS (Table 2). The rate of PTE after GKRS was 14%, 24%, and 24% at 6, 12, and 60 months, respectively (Figure 4).

Tumor size (≥25 mm) (p=0.004), tumor volume (≥5.3 ml) (p=0.038) and maximum dose (≥34 Gy) (p=0.005) were associated with PTE in univariate analysis. Tumor size (≥25 mm), maximum dose (≥34 Gy), tumor volume (≥5.3 ml) and tumor margin dose (≥14 Gy) were included in multivariate analysis. Only tumor size (≥25 mm) (Figure 5) and maximum dose (≥34 Gy) (Figure 6) were significantly associated with PTE [hazard ratio (HR)= 3.461, 95% confidence interval (CI)=1.157-10.356, p=0.026 and HR=3.067, 95% CI=1.068-8.809, P=0.037, respectively] (Table 3).

**DISCUSSION**

**Natural History of Meningiomas**

As many asymptomatic meningiomas has an indolent natural course. Understanding the natural history of them is of great importance to make appropriate management.
Sughrue et al. (17) performed a systematic review of 675 patients with untreated meningiomas followed with serial MR imaging from 22 studies. The authors found initial tumor diameter of 2–2.5 cm with the rapid growth of >10% per year was prone to occur symptom progression at a rate of 42%. They also found initial tumor diameter of >2.5 and 3 cm went on to develop new or worsened symptoms 17% of the time. In a recent meta-analysis, Nakasu et al. (12) also found large initial maximum diameter were significantly associated with symptomatic progression. As a high risk of symptom progression in large tumors, these patients may gain benefit from earlier treatment before the occurrence of symptoms.

Advantage and Limitation of Surgery

Surgical resection has advantages of rapid tumor removal and histopathologic analysis. Recent European Association of Neuro-Oncology guidelines indicates that surgery is the first option when treatment is indicated in meningioma of any WHO grade (18). However, surgical resection is an invasive treatment, depends on tumor location and can cause significant morbidity (12). In the study of Naslund et al. (19), 30-day complication rate was significantly higher among the asymptomatic cases. Besides, asymptomatic meningioma patients were less likely to work full time after surgical resection as compared with preoperative status. Yano et al. (20) reported older patients (>70 years) had a higher complication rate after surgical for asymptomatic meningiomas than younger patients (9.3% vs. 4.4%). For asymptomatic meningioma patients, surgical resection could make patients worse, at best unchanged (21). In the study of Jakola et al. (21), almost one in five patients developed subjective deterioration after surgery at a long-term follow up. Considering the potentially significant morbidity of surgery for asymptomatic meningiomas, surgical resection should be a more restrictive approach.

Gamma Knife Radiosurgery for Asymptomatic Meningiomas

A less invasive procedure, a low mortality and better function protection are the advantages of GKRS. These make GKRS more attractive and a preferred choice for asymptomatic meningiomas. A systematic review, meta-analysis and practice guideline (22) from international stereotactic radiosurgery society (ISRS) recommended radiosurgery may be proposed as a primary treatment modality for an asymptomatic or mildly symptomatic meningioma. Some authors (7, 10, 14, 15) had reported GKRS for asymptomatic meningiomas had a low tumor progression rate of 0%–5.9% and symptom progression rate of 2.6%–18%, as well as an acceptable rate of complications. Table 4 summarizes recent literature reporting GKRS for asymptomatic meningiomas. Jo et al. (7) reported 69 asymptomatic meningiomas underwent GKRS with mean follow up of 63.0 months. The mean tumor diameter was 17.3 (range, 7–31 mm). The tumor control rate was 100% with median margin dose of 14.5 (range, 12–20) Gy.

| Variables | Univariate, p | Multivariate, p | HR | 95% CI |
|-----------|--------------|----------------|----|-------|
| Age (≥55 years) | 0.935 | NA | NA | NA |
| Sex (male vs female) | 0.855 | NA | NA | NA |
| Skull base vs non skull base | 0.428 | NA | NA | NA |
| Tumor margin dose (≥14 Gy) | 0.100 | 0.477 | NA | NA |
| TV ≥5.3 ml | 0.038* | 0.118 | NA | NA |
| Tumor size (≥25 mm) | 0.004* | 0.026* | 3.461 | 1.157–10.356 |
| Maximum dose (≥34 Gy) | 0.005* | 0.003* | 3.067 | 1.068–8.809 |

CI, confidential interval; HR, hazards ratio; TV, tumor volume; NA, not available.

*Statistically significant (P < 0.05).
Transient complications developed in 39.1% of patients. There was no patient developed permanent neurologic deficit. Salvetti et al. (14) reported a tumor progression rate of 2.4% and permanent neurological deficit rate of 2.4% in 42 asymptomatic meningiomas treated with GKRS with a median margin dose of 15 (10–18) Gy. In this study, 23.8% of patients were small tumor (<20 mm). The proportion of prior surgical resection and radiotherapy were 45.2% and 4.8% respectively. Kim et al. (10) reported efficacy of proactive GKRS (n=153) in asymptomatic meningiomas compared with natural course (n=201). The radiological PFS rates in GKRS and observation group were 94.4% and 38.5% at 5 years, and 88.5% and 7.9% at 10 years, respectively. Adverse events developed in 13.3% of patients treated with GKRS, including 0.5% of patients requiring surgery due to severe edema after GKRS. 15.7% of patients in GKRS group presented peritumoral edema after GKRS. 15.3% of patients occurred new neurological deficits or surgery due to severe PTE. Univariate and multivariate analysis indicated large tumor size (≥20 mm) and maximum radiation dose (>16 Gy and tumor volume >10 cm³). Hoe et al. (31) reported 15.3% of patients developed new or increased PTE after GKRS. 8.8% of patients were symptomatic PTE. Treatment PTE, hemispheric tumor location and tumor volume larger than 4.2 cc were associated with PTE.

PTE at diagnosis had been reported to be associated with high-grade meningiomas (32). Therefore, patients with pretreatment PTE were excluded in this study. The result in this study was similar with previous studies. 25.4% of patients developed PTE after GKRS with median time of 7.2 (range, 2.0–81.6) months. Of this patients, seven cases (11.9%) were symptomatic PTE. One patient received surgical resection for severe PTE. Univariate and multivariate analysis indicated large tumor size (≥25 mm) and maximum radiation dose (≥34 Gy) were associated with PTE after GKRS.

**Study Limitations**

In this study, we restricted certain patients (large tumors, no PTE, and small tumors documented with growth) to undergo initial GKRS. This was a single-center retrospective study with selection and treatment biases. All of patients were diagnosed based on MRI or CT, and did not receive surgical resection before GKRS. Therefore, the histological diagnosis was not available. Besides, the number of patients in our study was small, which might affect statistical analysis. Finally, there was no control group to compare with those with natural course or treated with surgery.

**CONCLUSION**

In this single-center retrospective study, the results supported the efficacy and safety of initial GKRS for asymptomatic meningiomas. 98.3% of patients were under tumor control after GKRS. 15.3% of patients occurred new neurological symptoms or signs. For those large asymptomatic tumors or small tumors documented growth, initial GKRS could prevent tumor progression with an acceptable rate of complications.
GKRS could be an alternative treatment modality for selected asymptomatic meningiomas.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by The Second Affiliated Hospital of Guangzhou Medical University Institutional Review Board. The patients/participants provided their written informed consent to participate in this study.

REFERENCES

1. Jadid KD, Feychtling M, Hoijer J, Hylin S, Kihlstrom L, Mathiesen T. Long-term follow-up of incidentally discovered meningiomas. Acta Neurochir (Wien) (2015) 157(2):225–30; discussion 230. doi: 10.1007/s00701-014-2306-3
2. Kuratsu J, Kochi M, Uschio Y. Incidence and clinical features of asymptomatic meningiomas. J Neurosurg (2000) 92(5):766–70. doi: 10.3171/jns.2000.92.5.766
3. Bondy M, Ligon BL. Epidemiology and etiology of intracranial meningiomas: a review. J Neurooncol (1996) 29(3):197–205. doi: 10.1007/BF00165649
4. Ostrom QT, Curet J, Hamou MF, Yoon S, Liu PY, Wolinsky JS, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. Neuro Oncol (2019) 21 (Suppl 5):v1–v100. doi: 10.1093/neuonc/noz150
5. Hashiba T, Hashimoto N, Izumoto S, Suzuki T, Kagawa N, Maruno M, et al. Serial volumetric assessment of the natural history and growth pattern of incidentally discovered meningiomas. J Neurosurg (2009) 110(4):675–84. doi: 10.3171/2008.8.INS08481
6. Oya S, Kim SH, Sade B, Lee JH. The natural history of intracranial meningiomas. J Neurosurg (2011) 114(5):1250–6. doi: 10.3171/2010.12.JNS101623
7. Jo KW, Kim CH, Kong DS, Seol HJ, Nam DH, Park K, et al. Treatment modalities and outcomes for asymptomatic meningiomas. Acta Neurochir (Wien) (2011) 153(1):62–7; discussion 7. doi: 10.1007/s00701-010-0841-0
8. Nakamura M, Roser F, Michel J, Jacobs C, Samii M. The natural history of meningiomas. Neurosurgery (2003) 53(1):62–70; discussion 1. doi: 10.1227/01.neu.0000068730.76856.58
9. Yoneoka Y, Fujii Y, Tanaka R. Growth of incidental meningiomas. Acta Neurochir (Wien) (2000) 142(5):507–11. doi: 10.1007/s007010050463
10. Kim KH, Kang SJ, Choi JW, Kang DS, Seol HJ, Nam DH, et al. Clinical and radiological outcomes of proactive Gamma Knife surgery for asymptomatic meningiomas compared with the natural course without intervention. J Neurosurg (2018) 130(1–2):10. doi: 10.3171/2017.12.JNS171943
11. Agarwal V, McCutcheon BA, Hughes JD, Carlson ML, Glasgow AE, Habermann EB, et al. Trends in Management of Intracranial Meningiomas: Analysis of 49,921 Cases from Modern Cohort. World Neurosurg (2017) 106:145–51. doi: 10.1016/j.wneu.2017.06.127
12. Nakasu S, Nakasu Y. Natural History of Meningiomas: Review with Meta-analyses. Neurol Med Chir (2020) 60(3):109–20. doi: 10.2176/nmc.ra.2019-0213
13. Reinert M, Babey M, Curschmann J, Vajtai I, Seiler RW, Mariani L. Morbidity in 201 patients with small sized meningioma treated by microsurgery. Acta Neurochir (Wien) (2006) 148(12):1257–65; discussion 66. doi: 10.1007/s00701-006-0909-2
14. Salvetti DJ, Nagaraja TG, Levy C, Xu Z, Sheehan J. Gamma Knife surgery for the treatment of patients with asymptomatic meningiomas. J Neurosurg (2013) 119(2):487–93. doi: 10.3171/2013.3.JNS121746
15. Gupta A, Xu Z, Cohen-Inbar O, Snyder MH, Hobbs LK, Li C, et al. Treatment of Asymptomatic Meningioma With Gamma Knife Radiosurgery: Long-Term Follow-up With Volumetric Assessment and Clinical Outcome. Neurosurgery (2019) 85(5):E889–E99. doi: 10.1093/neuros/nyz126
16. Islam AI, Kalamannage-Dona R, Mohan M, Moon RDC, Crofton A, Haylock BJ, et al. A prognostic model to personalize monitoring regimes for patients with incidental asymptomatic meningiomas. Neuro Oncol (2020) 22(2):278–89. doi: 10.1093/neuonc/noz160
17. Sughrue ME, Rutkowsi MJ, Aranda D, Barani JJ, McDermott MW, Parsa AT. Treatment decision making based on the published natural history and growth rate of small meningiomas. J Neurosurg (2010) 113(5):1036–42. doi: 10.3171/2010.3.JNS091966
18. Goldbrunner R, Minniti G, Preusser M, Jenkinson MD, Sallabanda K, Houdart E, et al. EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol (2016) 17(9):e383–91. doi: 10.1016/S1470-2045(16)30321-7
19. Naslund O, Skoglund T, Farahmand D, Bonnleh D, Jakola AS. Indications and outcome in surgically treated asymptomatic meningiomas: a single-center case-control study. Acta Neurochir (Wien) (2020) 162. doi: 10.1007/s00701-020-02444-6
20. Yano S, Kuratsu J, Kumatomo Brain Tumor Research G. Indications for surgery in patients with asymptomatic meningiomas based on an extensive experience. J Neurosurg (2006) 105(4):538–43. doi: 10.3171/jns.2006.105.4.538
21. Jakola AS, Gulati M, Gulati S, Solheim O. The influence of surgery on quality of life in patients with intracranial meningiomas: a prospective study. J Neurooncol (2012) 110(1):137–44. doi: 10.1007/s11060-012-0947-8
22. Marchetti M, Sahgal A, De Salles AAF, Levivier M, Ma L, Paddick I, et al. Stereotactic Radiosurgery for Intracranial Noncavernous Sinus Benign Meningioma: International Stereotactic Radiosurgery Society Systematic Review, Meta-analysis and Practice Guideline. Neurosurgery (2020) 87. doi: 10.1093/neuros/nyaa169
23. Cai R, Barnett GH, Novak E, Chao ST, Suh JH. Principal risk of peritumoral edema after stereotactic radiosurgery for intracranial meningioma is tumor-brain contact interface area. Neurosurgery (2010) 66(5):513–22. doi: 10.1227/01.neu.0000365366.5337.88
24. Wang X, Chen JH, Chang JW, Chen Y, Chung SS. Complications after gamma knife radiotherapy for benign meningiomas. J Neurooncol (2003) 74(2):226–30. doi: 10.1023/A:1011363974226
25. Kollova A, Liscak R, Novotny J Jr., Vladyka V, Simonova G, Janouskova L. Gamma Knife surgery for benign meningioma. J Neurosurg (2007) 104:235–36. doi: 10.1211/JNS060751
26. Kuhn EN, Taksler GB, Dayton O, Loganathan A, Bourland D, Tatter SB, et al. Is there a tumor volume threshold for postradiosurgical symptoms? A single-institution analysis. Neurosurgery (2014) 75(5):536–45; discussion 44–5; quiz 45. doi: 10.1227/NEU.0000000000000519

AUTHOR CONTRIBUTIONS

LW, CP, XY, HY, LC, and YD collected the data. JF, LW, CP, and XY analyzed the data. JY, JF, and LW wrote the paper. JY conceived and designed the study. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by National Key Research and Development Project (grants number: 2017YFC0113700); National Natural Science Foundation of China (grants number: 81902928). China Postdoctoral Science Foundation Funded Project (2018M643343); Doctoral initiation project of Second Affiliated Hospital of Guangzhou medical university (010G271104).
27. Lee SR, Yang KA, Kim SK, Kim SH. Radiation-induced intratumoral necrosis and peritumoral edema after gamma knife radiosurgery for intracranial meningiomas. *J Korean Neurosurg Soc* (2012) 52(2):98–102. doi: 10.3340/jkns.2012.52.2.98

28. Mansouri A, Larjani S, Kârînomos G, Laperriere N, Casimano M, Gentili F, et al. Predictors of response to Gamma Knife radiosurgery for intracranial meningiomas. *J Neurosurg* (2015) 123(5):1294–300. doi: 10.3171/2014.12.JNS141687

29. Novotny J Jr., Kollova A, Liscak R. Prediction of intracranial edema after radiosurgery of meningiomas. *J Neurosurg* (2006) 105 Suppl:120–6. doi: 10.3171/sup.2006.105.7.120

30. Singh VP, Kansai S, Vaishya S, Julka PK, Mehta VS. Early complications following gamma knife radiosurgery for intracranial meningiomas. *J Neurosurg* (2000) 93 Suppl 3:57–61. doi: 10.3171/jns.2000.93.suppement

31. Hoe Y, Choi YJ, Kim JH, Kwon DH, Kim CJ, Cho YH. Peritumoral Brain Edema after Stereotactic Radiosurgery for Asymptomatic Intracranial Meningiomas: Risks and Pattern of Evolution. *J Korean Neurosurg Soc* (2015) 58(4):379–84. doi: 10.3340/jkns.2015.58.4.379

32. Ressel A, Fichte S, Brodhun M, Rosahl SK, Gerlach R. WHO grade of intracranial meningiomas differs with respect to patient’s age, location, tumor size and peritumoral edema. *J Neurooncol* (2019) 145(2):277–86. doi: 10.1007/s11060-019-03293-x

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Fu, Wu, Peng, Yang, You, Cao, Deng and Yu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.